Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Operations (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Cash from Operations data on record, last reported at 32203000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 1.89% year-over-year to 32203000.0; the TTM value through Dec 2025 reached 128512000.0, down 209.24%, while the annual FY2025 figure was 128512000.0, 209.24% down from the prior year.
  • Cash from Operations reached 32203000.0 in Q4 2025 per TRDA's latest filing, down from 28313000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 203399000.0 in Q1 2023 and bottomed at 38507000.0 in Q1 2025.
  • Average Cash from Operations over 4 years is 7753250.0, with a median of 26411500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: surged 1068.98% in 2023, then crashed 687.57% in 2024.
  • A 4-year view of Cash from Operations shows it stood at 27304000.0 in 2022, then surged by 85.3% to 4013000.0 in 2023, then plummeted by 687.57% to 31605000.0 in 2024, then fell by 1.89% to 32203000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 32203000.0 in Q4 2025, 28313000.0 in Q3 2025, and 29489000.0 in Q2 2025.